

Thomas Mller

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5649675/thomas-muller-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113
papers

3,270
citations

29
h-index

53
g-index

124
ext. papers

3,685
ext. citations

4.3
avg, IF

5.8
L-index

#	Paper	IF	Citations
113	Memantine for Treatment of Dementia 2022 , 1-9		
112	Perspective: cell death mechanisms and early diagnosis as precondition for disease modification in Parkinson's disease: are we on the right track?. <i>Expert Review of Molecular Diagnostics</i> , 2022 , 1-7	3.8	0
111	Complex motion series performance differs between previously untreated patients with Parkinson's disease and controls. <i>Journal of Neural Transmission</i> , 2021 , 1	4.3	
110	Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the Evidence. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 397-408	3	0
109	Perspective: Treatment for Disease Modification in Chronic Neurodegeneration. <i>Cells</i> , 2021 , 10,	7.9	6
108	View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track?. <i>Biologics: Targets and Therapy</i> , 2021 , 15, 307-316	4.4	
107	An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1659-1665	4	0
106	Kinesiology training in patients with Parkinson's disease: results of a pilot study. <i>Journal of Neural Transmission</i> , 2020 , 127, 793-798	4.3	0
105	Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2020 , 127, 265-272	4.3	2
104	Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 403-414	5.5	21
103	Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson's Disease 2020 , 1-18		
102	Pitfalls and possible solutions for research and development of dementia therapies 2020 , 547-558		
101	Management with monoamine oxidase B inhibitors in Parkinson's disease 2020 , 477-490		
100	Safinamide for Treating Parkinson's Disease 2020 , 1-8		
99	Safinamide in the treatment of Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2020 , 10, 195-204	2.8	3
98	Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2020 , 127, 1369-1376	4.3	0
97	Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson's Disease and Its Inherent Risk for Melanoma. <i>Cells</i> , 2019 , 8,	7.9	2

96	α-Synuclein in Parkinson's disease: causal or bystander?. <i>Journal of Neural Transmission</i> , 2019 , 126, 815-840.	4.3	53
95	Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1181-1187	4	16
94	Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 429-435	5.5	13
93	Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial. <i>Neurology</i> , 2019 , 92, e1487-e1496	6.5	12
92	Dynamics of Parkinson's Disease Multimodal Complex Treatment in Germany from 2010?2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers. <i>Cells</i> , 2019 , 8,	7.9	15
91	Bound, free, and total L-dopa measurement in plasma of Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2019 , 126, 1417-1420	4.3	0
90	Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia. <i>Drugs</i> , 2019 , 79, 1367-1374	3.4	9
89	Vitamin D rise enhances blood perfusion in patients with multiple sclerosis. <i>Journal of Neural Transmission</i> , 2019 , 126, 1631-1636	4.3	4
88	Therapiefreiheit zwischen gesetzlichem Rahmen und Zulassungsverfahren. <i>Neurotransmitter</i> , 2019 , 30, 16-21	0.1	
87	Landscape of pain in Parkinson's disease: impact of gender differences. <i>Neurological Research</i> , 2019 , 41, 87-97	2.7	6
86	An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018 , 125, 953-963	4.3	11
85	Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects. <i>Journal of Neural Transmission</i> , 2018 , 125, 1751-1757	4.3	37
84	Safinamide: an add-on treatment for managing Parkinson's disease. <i>Clinical Pharmacology: Advances and Applications</i> , 2018 , 10, 31-41	1.5	9
83	Long-term management of Parkinson's disease using levodopa combinations. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1003-1011	4	9
82	Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson's disease. <i>Medical Hypotheses</i> , 2018 , 110, 46-49	3.8	3
81	Patientenperspektive auf die Versorgungssituation im Krankheitsbild Morbus Parkinson in Deutschland (eine Querschnittserhebung). <i>Aktuelle Neurologie</i> , 2018 , 45, 703-713		8
80	Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 2063-2071	4	8
79	Benefit on motor and non-motor behavior in a specialized unit for Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017 , 124, 715-720	4.3	25

78	Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 693-699	5.5	14
77	Classification of advanced stages of Parkinson's disease: translation into stratified treatments. <i>Journal of Neural Transmission</i> , 2017 , 124, 1015-1027	4.3	40
76	Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017 , 124, 745-748	4.3	7
75	Use of monoamine oxidase inhibitors in chronic neurodegeneration. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 233-240	5.5	43
74	Investigational agents for the management of Huntington's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 175-185	5.9	8
73	Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2017 , 40, 208-211	1.4	12
72	Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 251-261	6.2	33
71	Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017 , 7, 629-634	5.3	30
70	Hypomethylation in Parkinson's disease: An epigenetic drug effect?. <i>Movement Disorders</i> , 2016 , 31, 605-617	7	7
69	Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016 , 123, 401-6	4.3	22
68	Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective. <i>Neurodegenerative Disease Management</i> , 2016 , 6, 385-98	2.8	2
67	Catechol-O-methyltransferase inhibitors in Parkinson's disease. <i>Drugs</i> , 2015 , 75, 157-74	12.1	98
66	Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. <i>Journal of Neural Transmission</i> , 2015 , 122, 841-8	4.3	10
65	Targeting repulsive guidance molecule A to promote regeneration and neuroprotection in multiple sclerosis. <i>Cell Reports</i> , 2015 , 10, 1887-98	10.6	46
64	Meta-analysis of Placebo-controlled Clinical Trials of Safinamide and Entacapone as Add-on Therapy to Levodopa in the Treatment of Parkinson's Disease. <i>European Neurological Review</i> , 2015 , 10, 15	0.5	12
63	Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. <i>Journal of Neural Transmission</i> , 2014 , 121, 1357-66	4.3	14
62	Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. <i>Journal of Neural Transmission</i> , 2014 , 121, 379-83	4.3	27
61	Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1423-32	5.5	11

60	Tolcapone addition improves Parkinson's disease associated nonmotor symptoms. <i>Therapeutic Advances in Neurological Disorders</i> , 2014 , 7, 77-82	6.6	19
59	Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 501-7 ; discussion 501	3.6	77
58	Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013 , 120, 761-5	4.3	29
57	Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 707-18	4.3	32
56	Neuropsychological effects of deep brain stimulation for Parkinson's disease. <i>Surgical Neurology International</i> , 2013 , 4, S443-7	1	17
55	Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. <i>Clinical Neuropharmacology</i> , 2013 , 36, 84-91	1.4	18
54	Malnutritional neuropathy under intestinal levodopa infusion. <i>Journal of Neural Transmission</i> , 2012 , 119, 369-72	4.3	49
53	Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion. <i>Movement Disorders</i> , 2012 , 27, 1704-5	7	25
52	Drug therapy in patients with Parkinson's disease. <i>Translational Neurodegeneration</i> , 2012 , 1, 10	10.3	66
51	Psychiatric, nonmotor aspects of Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 106, 477-90	3	5
50	Motor complications, levodopa metabolism and progression of Parkinson's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 847-55	5.5	29
49	Pain perception, pain drug therapy and health status in patients with Parkinson's disease. <i>Neuroepidemiology</i> , 2011 , 37, 183-7	5.4	16
48	Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011 , 383, 627-33	3.4	7
47	Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson's Disease. <i>Pharmaceutics</i> , 2010 , 2, 313-320	6.4	7
46	The Impact of COMT-inhibition on Gastrointestinal Levodopa Absorption in Patients with Parkinson's Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2010 , 2, CMT.S1169	0	11
45	Effect of exercise on reactivity and motor behaviour in patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 747-53	5.5	32
44	Entacapone. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010 , 6, 983-93	5.5	16
43	Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010 , 16, 688-9	3.6	14

42	Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1339-43	7	28
41	Peripheral COMT inhibition prevents levodopa associated homocysteine increase. <i>Journal of Neural Transmission</i> , 2009 , 116, 1253-6	4.3	15
40	Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells. <i>Neurological Research</i> , 2008 , 30, 417-9	2.7	6
39	Role of homocysteine in the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 957-67	4.3	39
38	Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. <i>Clinical Neuropharmacology</i> , 2008 , 31, 134-40	1.4	11
37	Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2008 , 115, 851-5	4.3	11
36	Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. <i>Movement Disorders</i> , 2008 , 23, 145-6	7	20
35	Placebo influences on dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 700-7	7	99
34	Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. <i>Movement Disorders</i> , 2007 , 22, 179-86	7	223
33	Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease. <i>Clinical Neuropharmacology</i> , 2007 , 30, 101-6	1.4	20
32	Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007 , 13, 466-79	3.6	45
31	Entacapone improves complex movement performance in patients with Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2007 , 14, 424-8	2.2	10
30	Complex movement behaviour and progression of Huntington's disease. <i>Neuroscience Letters</i> , 2007 , 416, 272-4	3.3	23
29	Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2007 , 422, 119-22	3.3	7
28	Rivastigmine in the treatment of patients with Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2007 , 3, 211-8	3.1	23
27	Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 447-50	2.8	39
26	Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. <i>Movement Disorders</i> , 2006 , 21, 332-6	7	41
25	Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1715-30	4	58

24	Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. <i>Clinical Neuropharmacology</i> , 2006 , 29, 61-7	1.4	99
23	Diagnostic aspects of early Parkinson's disease. <i>Journal of Neurology</i> , 2006 , 253 Suppl 4, IV29-31	5.5	1
22	Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease. <i>Clinical Neuropharmacology</i> , 2005 , 28, 238-40	1.4	6
21	Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. <i>Archives of Neurology</i> , 2004 , 61, 657-60		84
20	Is levodopa toxic?. <i>Journal of Neurology</i> , 2004 , 251 Suppl 6, VI/44-6	5.5	30
19	Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic. <i>CNS Drugs</i> , 2004 , 18, 105-11	6.7	18
18	Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2004 , 363, 284-7	3.3	27
17	Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. <i>Psychosomatic Medicine</i> , 2004 , 66, 538-47	3.7	57
16	Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2003 , 339, 25-8	3.3	32
15	Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2003 , 341, 201-4	3.3	157
14	Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics. <i>NeuroRehabilitation</i> , 2003 , 18, 271-5	2	1
13	Drug treatment of non-motor symptoms in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 381-8	4	11
12	Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients. <i>Canadian Journal of Neurological Sciences</i> , 2002 , 29, 73-7	1	20
11	Dopaminergic substitution in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 1393-403 ₄		23
10	Apomorphine delays simple reaction time in Parkinsonian patients. <i>Parkinsonism and Related Disorders</i> , 2002 , 8, 357-60	3.6	10
9	CPI-1189. Centaur. <i>Current Opinion in Investigational Drugs</i> , 2002 , 3, 1763-7		1
8	Non-dopaminergic drug treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 557-72	4	11
7	Delay of simple reaction time after levodopa intake. <i>Clinical Neurophysiology</i> , 2001 , 112, 2133-7	4.3	23

6	Integrity of the blood-cerebrospinal fluid barrier in early Parkinson's disease. <i>Neuroscience Letters</i> , 2001 , 300, 182-4	3.3	32
5	Correlation between tapping and inserting of pegs in Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 2000 , 27, 311-5	1	48
4	Choice reaction time after levodopa challenge in parkinsonian patients. <i>Journal of the Neurological Sciences</i> , 2000 , 181, 98-103	3.2	24
3	No increase of synthesis of (R)salsolinol in Parkinson's disease. <i>Movement Disorders</i> , 1999 , 14, 514-5	7	12
2	The neuroimmune hypothesis in Parkinson's disease. <i>Reviews in the Neurosciences</i> , 1997 , 8, 29-34	4.7	14
1	Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. <i>Neuroscience Letters</i> , 1995 , 202, 17-20	3.3	618